CD8+ t cell based immunosuppressive tumor microenvironment detection method
US-11881286-B2 · Jan 23, 2024 · US
Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer
US10058591B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10058591-B2 |
| Application number | US-201514958485-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 3, 2015 |
| Priority date | Nov 17, 2011 |
| Publication date | Aug 28, 2018 |
| Grant date | Aug 28, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a combination of a parvovirus and a cytokine, preferably IFN y , for use in treating pancreatic cancer, in particular a terminal stage of this disease.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating terminal stage pancreatic cancer characterized by peritoneal carcinosis in a patient suffering from a terminal stage pancreatic cancer that is characterized by peritoneal carcinosis, comprising administering to the patient an effective dose of a combination of parvovirus HI (H1-PV) and interferon-γ (IFN-γ), wherein said parvovirus is administered intratumorally and the IFN-γ is administered intraperitoneally, wherein the combination further comprises an immunosuppressive agent, further wherein said treatment increases survival of the patient suffering from terminal stage pancreatic cancer characterized by peritoneal carcinosis as compared to survival of a patient who has not received said treatment. 2. The method of claim 1 , wherein the immunosuppressive agent is rapamycin or cyclophosphamide.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
- A61K38/217Primary
IFN-gamma · CPC title
Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766 · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10058591B2 cover?
- The present invention relates to a combination of a parvovirus and a cytokine, preferably IFN y , for use in treating pancreatic cancer, in particular a terminal stage of this disease.
- Who is the assignee on this patent?
- Univ Heidelberg Ruprecht Karls, Deutsches Krebsforschung Szentrum, Deutsches Krebsforsch
- What technology area does this patent fall under?
- Primary CPC classification A61K38/217. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).